Advanced search
Publication Cover
Critical Reviews in Biochemistry and Molecular Biology Volume 53, 2018 - Issue 5
Submit an article Journal homepage
5,603
Views
38
CrossRef citations to date
0
Altmetric
Review Article

The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases

Neel H. ShahDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA; ;Department of Chemistry, University of California, Berkeley, CA, USA; ;California Institute for Quantitative Biosciences, University of California, Berkeley, CA, USA; ;Howard Hughes Medical Institute, University of California, Berkeley, CA, USA; ORCID Iconhttp://orcid.org/0000-0002-1186-0626View further author information
ORCID Icon,
Jeanine F. AmacherDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA; ;Department of Chemistry, University of California, Berkeley, CA, USA; ;California Institute for Quantitative Biosciences, University of California, Berkeley, CA, USA; ;Howard Hughes Medical Institute, University of California, Berkeley, CA, USA; ORCID Iconhttp://orcid.org/0000-0002-3646-7521View further author information
ORCID Icon,
Laura M. NockaDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA; ;Department of Chemistry, University of California, Berkeley, CA, USA; ;California Institute for Quantitative Biosciences, University of California, Berkeley, CA, USA; ;Howard Hughes Medical Institute, University of California, Berkeley, CA, USA; ORCID Iconhttp://orcid.org/0000-0003-2556-4227View further author information
ORCID Icon &
John KuriyanDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA; ;Department of Chemistry, University of California, Berkeley, CA, USA; ;California Institute for Quantitative Biosciences, University of California, Berkeley, CA, USA; ;Howard Hughes Medical Institute, University of California, Berkeley, CA, USA; ;Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4414-5477View further author information
ORCID Icon
Pages 535-563 | Received 22 May 2018, Accepted 27 Jun 2018, Published online: 05 Sep 2018

References

  • Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, et al. 2006. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2:95–102.
  • Agafonov RV, Wilson C, Otten R, Buosi V, Kern D. 2014. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Nat Struct Mol Biol. 21:848–853.
  • Aleem SU, Craddock BP, Miller WT. 2015. Constitutive activity in an ancestral form of abl tyrosine kinase. PLoS One. 10:e0131062.
  • Andreotti AH, Joseph RE, Conley JM, Iwasa J, Berg LJ. 2018. Multidomain control over TEC kinase activation state tunes the T cell response. Annu Rev Immunol. 36:549–578.
  • Arbesú M, Maffei M, Cordeiro TN, Teixeira JMC, Pérez Y, Bernadó P, Roche S, Pons M. 2017. The unique domain forms a fuzzy intramolecular complex in Src family kinases. Structure. 25:630–640.e4.
  • Azam M, Latek RR, Daley GQ. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:831–843.
  • Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. 2008. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 15:1109–1118.
  • Banavali NK, Roux B. 2009. Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases. Proteins. 74:378–389.
  • Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P, Comoglio PM. 1998. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci USA. 95:14379–14383.
  • Begley MJ, Yun C, Gewinner CA, Asara JM, Johnson JL, Coyle AJ, Eck MJ, Apostolou I, Cantley LC. 2015. EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src. Nat Struct Mol Biol. 22:983–990.
  • Bender AT, Gardberg A, Pereira A, Johnson T, Wu Y, Grenningloh R, Head J, Morandi F, Haselmayer P, Liu-Bujalski L. 2017. Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of fc receptor but not B-cell receptor signaling. Mol Pharmacol. 91:208–219.
  • Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. 1986. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 233:212–214.
  • Bergman M, Joukov V, Virtanen I, Alitalo K. 1995. Overexpressed Csk tyrosine kinase is localized in focal adhesions, causes reorganization of alpha v beta 5 integrin, and interferes with HeLa cell spreading. Mol Cell Biol. 15:711–722.
  • Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature. 411:355–365.
  • Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, Fischer S, Romeo G, Rossi B. 1997. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene. 15:2257–2265.
  • Boggon TJ, Eck MJ. 2004. Structure and regulation of Src family kinases. Oncogene. 23:7918–7927.
  • Booker GW, Breeze AL, Downing AK, Panayotou G, Gout I, Waterfield MD, Campbell ID. 1992. Structure of an SH2 domain of the p85 alpha subunit of phosphatidylinositol-3-OH kinase. Nature. 358:684–687.
  • Bose R, Holbert MA, Pickin KA, Cole PA. 2006. Protein tyrosine kinase-substrate interactions. Curr Opin Struct Biol. 16:668–675.
  • Boyken SE, Chopra N, Xie Q, Joseph RE, Wales TE, Fulton DB, Engen JR, Jernigan RL, Andreotti AH. 2014. A conserved isoleucine maintains the inactive state of Bruton’s tyrosine kinase. J Mol Biol. 426:3656–3669.
  • Bradham CA, Foltz KR, Beane WS, Arnone MI, Rizzo F, Coffman JA, Mushegian A, Goel M, Morales J, Geneviere A-M, et al. 2006. The sea urchin kinome: a first look. Dev Biol. 300:180–193.
  • Brasher BB, Van Etten RA. 2000. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem. 275:35631–35637.
  • Chung JK, Nocka LM, Wang Q, Kadlecek TA, Weiss A, Kuriyan J, Groves JT. 2018. Switch-like activation of Bruton’s tyrosine kinase by membrane-mediated dimerization. BioRxiv DOI:10.1101/284000.
  • Courtney AH, Amacher JF, Kadlecek TA, Mollenauer MN, Au-Yeung BB, Kuriyan J, Weiss A. 2017. A phosphosite within the SH2 domain of Lck regulates its activation by CD45. Mol Cell. 67:498–511.e6.
  • Couture C, Songyang Z, Jascur T, Williams S, Tailor P, Cantley LC, Mustelin T. 1996. Regulation of the Lck SH2 domain by tyrosine phosphorylation. J Biol Chem. 271:24880–24884.
  • Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. 2005. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure. 13:861–871.
  • Dar AC, Lopez MS, Shokat KM. 2008. Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem Biol. 15:1015–1022.
  • De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. 1993. Crystal structure of cyclin-dependent kinase 2. Nature. 363:595–602.
  • Debnath J, Chamorro M, Czar MJ, Schaeffer EM, Lenardo MJ, Varmus HE, Schwartzberg PL. 1999. rlk/TXK encodes two forms of a novel cysteine string tyrosine kinase activated by Src family kinases. Mol Cell Biol. 19:1498–1507.
  • Deng Y, Alicea-Velázquez NL, Bannwarth L, Lehtonen SI, Boggon TJ, Cheng H-C, Hytönen VP, Turk BE. 2014. Global analysis of human nonreceptor tyrosine kinase specificity using high-density peptide microarrays. J Proteome Res. 13:4339–4346.
  • Devkota S, Joseph RE, Boyken SE, Fulton DB, Andreotti AH. 2017. An autoinhibitory role for the pleckstrin homology domain of interleukin-2-inducible tyrosine kinase and its interplay with canonical phospholipid recognition. Biochemistry. 56:2938–2949.
  • Eck MJ, Shoelson SE, Harrison SC. 1993. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature. 362:87–91.
  • Feng S, Chen JK, Yu H, Simon JA, Schreiber SL. 1994. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science. 266:1241–1247.
  • Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, et al. 2008. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell. 134:793–803.
  • Foda ZH, Shan Y, Kim ET, Shaw DE, Seeliger MA. 2015. A dynamically coupled allosteric network underlies binding cooperativity in Src kinase. Nat Commun. 6:5939.
  • Gan W, Yang S, Roux B. 2009. Atomistic view of the conformational activation of Src kinase using the string method with swarms-of-trajectories. Biophys J. 97:L8–L10.
  • Goff SP, Gilboa E, Witte ON, Baltimore D. 1980. Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell. 22:777–785.
  • Goodfellow HS, Frushicheva MP, Ji Q, Cheng DA, Kadlecek TA, Cantor AJ, Kuriyan J, Chakraborty AK, Salomon A, Weiss A. 2015. The catalytic activity of the kinase ZAP-70 mediates basal signaling and negative feedback of the T cell receptor pathway. Sci Signal. 8:ra49.
  • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:876–880.
  • Grasis JA, Tsoukas CD. 2011. Itk: the rheostat of the T cell response. J Signal Transduct. 2011:297868.
  • Grassilli E, Pisano F, Cialdella A, Bonomo S, Missaglia C, Cerrito MG, Masiero L, Ianzano L, Giordano F, Cicirelli V, et al. 2016. A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. Oncogene. 35:4368–4378.
  • Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, et al. 2006. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 26:6082–6093.
  • Guo S, Wahl MI, Witte ON. 2006. Mutational analysis of the SH2-kinase linker region of Bruton’s tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. Int Immunol. 18:79–87.
  • Hantschel O. 2012. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer. 3:436–446.
  • Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G. 2003. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 112:845–857.
  • Hantschel O, Wiesner S, Güttler T, Mackereth CD, Rix LLR, Mikes Z, Dehne J, Görlich D, Sattler M, Superti-Furga G. 2005. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell. 19:461–473.
  • Harms MJ, Thornton JW. 2013. Evolutionary biochemistry: revealing the historical and physical causes of protein properties. Nat Rev Genet. 14:559–571.
  • Hendriks RW, Yuvaraj S, Kil LP. 2014. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 14:219–232.
  • Heyeck SD, Wilcox HM, Bunnell SC, Berg LJ. 1997. Lck phosphorylates the activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity. J Biol Chem. 272:25401–25408.
  • Hubbard SR. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:5572–5581.
  • Hubbard SR, Miller WT. 2007. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 19:117–123.
  • Hui E, Vale RD. 2014. In vitro membrane reconstitution of the T-cell receptor proximal signaling network. Nat Struct Mol Biol. 21:133–142.
  • Hunter T. 2009. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 21:140–146.
  • Hunter T, Sefton BM. 1980. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA. 77:1311–1315.
  • Huse M, Kuriyan J. 2002. The conformational plasticity of protein kinases. Cell. 109:275–282.
  • Hyvönen M, Saraste M. 1997. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J. 16:3396–3404.
  • Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. 1999. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet. 21:187–190.
  • Jahnke W, Grotzfeld RM, Pellé X, Strauss A, Fendrich G, Cowan-Jacob SW, Cotesta S, Fabbro D, Furet P, Mestan J, et al. 2010. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc. 132:7043–7048.
  • Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massagué J, Pavletich NP. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 376:313–320.
  • Johnson LN. 2009. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys. 42:1–40.
  • Joseph RE, Fulton DB, Andreotti AH. 2007. Mechanism and functional significance of Itk autophosphorylation. J Mol Biol. 373:1281–1292.
  • Joseph RE, Kleino I, Wales TE, Xie Q, Fulton DB, Engen JR, Berg LJ, Andreotti AH. 2013. Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases. Sci Signal. 6:ra76.
  • Joseph RE, Wales TE, Fulton DB, Engen JR, Andreotti AH. 2017. Achieving a graded immune response: BTK adopts a range of active/inactive conformations dictated by multiple interdomain contacts. Structure. 25:1481–1494.e4.
  • Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. 2011. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell. 42:9–22.
  • Kato JY, Takeya T, Grandori C, Iba H, Levy JB, Hanafusa H. 1986. Amino acid substitutions sufficient to convert the nontransforming p60c-Src protein to a transforming protein. Mol Cell Biol. 6:4155–4160.
  • Katz ZB, Novotná L, Blount A, Lillemeier BF. 2017. A cycle of Zap70 kinase activation and release from the TCR amplifies and disperses antigenic stimuli. Nat Immunol. 18:86–95.
  • Kim PW, Sun Z-YJ, Blacklow SC, Wagner G, Eck MJ. 2003. A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8. Science. 301:1725–1728.
  • King N, Carroll SB. 2001. A receptor tyrosine kinase from choanoflagellates: molecular insights into early animal evolution. Proc Natl Acad Sci USA. 98:15032–15037.
  • King N, Hittinger CT, Carroll SB. 2003. Evolution of key cell signaling and adhesion protein families predates animal origins. Science. 301:361–363.
  • Kornev AP, Haste NM, Taylor SS, Eyck LFT. 2006. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103:17783–17788.
  • Kornev AP, Taylor SS. 2015. Dynamics-Driven Allostery in Protein Kinases. Trends Biochem Sci. 40:628–647.
  • Kornev AP, Taylor SS, Ten Eyck LF. 2008. A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci USA. 105:14377–14382.
  • Krishnamurty R, Maly DJ. 2010. Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol. 5:121–138.
  • Kuriyan J, Cowburn D. 1997. Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct. 26:259–288.
  • Kuriyan J, Eisenberg D. 2007. The origin of protein interactions and allostery in colocalization. Nature. 450:983–990.
  • Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O. 2013. Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochim Biophys Acta. 1834:1449–1459.
  • Lamontanara AJ, Georgeon S, Tria G, Svergun DI, Hantschel O. 2014. The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility. Nat Commun. 5:5470.
  • Lee BJ, Shah NP. 2017. Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. Leukemia. 31:1096–1107.
  • Lee S, Ayrapetov MK, Kemble DJ, Parang K, Sun G. 2006. Docking-based substrate recognition by the catalytic domain of a protein tyrosine kinase, C-terminal Src kinase (Csk). J Biol Chem. 281:8183–8189.
  • Lee S, Lin X, Nam NH, Parang K, Sun G. 2003. Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc Natl Acad Sci USA. 100:14707–14712.
  • Lemmon MA. 2008. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol. 9:99–111.
  • Lemmon MA, Ferguson KM. 2000. Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem J. 350Pt 1:1–18.
  • Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell. 141:1117–1134.
  • Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, Karplus M, Cole PA, Kuriyan J. 2006. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4:e144.
  • Levinson NM, Seeliger MA, Cole PA, Kuriyan J. 2008. Structural basis for the recognition of c-Src by its inactivator Csk. Cell. 134:124–134.
  • Levy JB, Iba H, Hanafusa H. 1986. Activation of the transforming potential of p60c-Src by a single amino acid change. Proc Natl Acad Sci USA. 83:4228–4232.
  • Li W, Young SL, King N, Miller WT. 2008. Signaling properties of a non-metazoan Src kinase and the evolutionary history of Src negative regulation. J Biol Chem. 283:15491–15501.
  • Lim WA, Pawson T. 2010. Phosphotyrosine signaling: evolving a new cellular communication system. Cell. 142:661–667.
  • Lim WA, Richards FM, Fox RO. 1994. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature. 372:375–379.
  • Lin X, Lee S, Sun G. 2003. Functions of the activation loop in Csk protein-tyrosine kinase. J Biol Chem. 278:24072–24077.
  • Lin Y-L, Meng Y, Jiang W, Roux B. 2013. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc Natl Acad Sci USA. 110:1664–1669.
  • Lorenz S, Deng P, Hantschel O, Superti-Furga G, Kuriyan J. 2015. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity. Biochem J. 468:283–291.
  • Manning G, Plowman GD, Hunter T, Sudarsanam S. 2002a. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci. 27:514–520.
  • Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002b. The protein kinase complement of the human genome. Science. 298:1912–1934.
  • Manning G, Young SL, Miller WT, Zhai Y. 2008. The protist, Monosiga brevicollis, has a tyrosine kinase signaling network more elaborate and diverse than found in any known metazoan. Proc Natl Acad Sci USA 105:9674–9679.
  • Mano H. 1999. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev. 10:267–280.
  • Martin GS. 2004. The road to Src. Oncogene. 23:7910–7917.
  • Mayer BJ, Hamaguchi M, Hanafusa H. 1988. Characterization of p47gag-crk, a novel oncogene product with sequence similarity to a putative modulatory domain of protein-tyrosine kinases and phospholipase C. Cold Spring Harb Symp Quant Biol. 53:907–914.
  • Mayer BJ, Hirai H, Sakai R. 1995. Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases. Curr Biol. 5:296–305.
  • McWhirter JR, Galasso DL, Wang JY. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 13:7587–7595.
  • Meharena HS, Chang P, Keshwani MM, Oruganty K, Nene AK, Kannan N, Taylor SS, Kornev AP. 2013. Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol. 11:e1001680.
  • Meng Y, Ahuja LG, Kornev AP, Taylor SS, Roux B. 2018. A catalytically disabled double mutant of Src tyrosine kinase can be stabilized into an active-like conformation. J Mol Biol. 430:881–889.
  • Meng Y, Pond MP, Roux B. 2017. Tyrosine Kinase Activation and Conformational Flexibility: Lessons from Src-Family Tyrosine Kinases. Acc Chem Res. 50:1193–1201.
  • Meng Y, Roux B. 2014. Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. J Mol Biol. 426:423–435.
  • Meng Y, Shukla D, Pande VS, Roux B. 2016. Transition path theory analysis of c-Src kinase activation. Proc Natl Acad Sci USA. 113:9193–9198.
  • Miller WT. 2003. Determinants of substrate recognition in nonreceptor tyrosine kinases. Acc Chem Res. 36:393–400.
  • Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, Miller WT. 1997. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 385:650–653.
  • Mócsai A, Ruland J, Tybulewicz VLJ. 2010. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 10:387–402.
  • Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang B-C, Wilson KP. 2004. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 279:31655–31663.
  • Musacchio A, Noble M, Pauptit R, Wierenga R, Saraste M. 1992. Crystal structure of a Src-homology 3 (SH3) domain. Nature. 359:851–855.
  • Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:4236–4243.
  • Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J. 2006. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell. 21:787–798.
  • Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. 2003. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:859–871.
  • Noble MEM, Endicott JA, Johnson LN. 2004. Protein kinase inhibitors: insights into drug design from structure. Science. 303:1800–1805.
  • Nolen B, Taylor S, Ghosh G. 2004. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell. 15:661–675.
  • Nowell P, Hungerford D. 1960. A minute chromosome in human chronic granulocytic leukemia. Science. 132:1497–1501.
  • Ogawa A, Takayama Y, Sakai H, Chong KT, Takeuchi S, Nakagawa A, Nada S, Okada M, Tsukihara T. 2002. Structure of the carboxyl-terminal Src kinase, Csk. J Biol Chem. 277:14351–14354.
  • Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. 1991. CSK: a protein-tyrosine kinase involved in regulation of Src family kinases. J Biol Chem. 266:24249–24252.
  • Okada M, Nakagawa H. 1989. A protein tyrosine kinase involved in regulation of pp60c-Src function. J Biol Chem. 264:20886–20893.
  • Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, Garrett MD, Mittnacht S, Pearl LH. 2006. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 25:3179–3190.
  • Oppermann H, Levinson AD, Varmus HE, Levintow L, Bishop JM. 1979. Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (Src). Proc Natl Acad Sci USA 76:1804–1808.
  • Overduin M, Rios CB, Mayer BJ, Baltimore D, Cowburn D. 1992. Three-dimensional solution structure of the Src homology 2 domain of c-abl. Cell. 70:697–704.
  • Ozkirimli E, Post CB. 2006. Src kinase activation: A switched electrostatic network. Protein Sci. 15:1051–1062.
  • Pan Z, Scheerens H, Li S-J, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KCK, Grothaus PG, et al. 2007. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem. 2:58–61.
  • Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C, Scharenberg AM, Kinet JP, Witte ON. 1996. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 4:515–525.
  • Pawson T, Kofler M. 2009. Kinome signaling through regulated protein-protein interactions in normal and cancer cells. Curr Opin Cell Biol. 21:147–153.
  • Pawson T, Nash P. 2000. Protein-protein interactions define specificity in signal transduction. Genes Dev. 14:1027–1047.
  • Pellicena P, Miller WT. 2001. Processive phosphorylation of p130Cas by Src depends on SH3-polyproline interactions. J Biol Chem. 276:28190–28196.
  • Pellicena P, Stowell KR, Miller WT. 1998. Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites. J Biol Chem. 273:15325–15328.
  • Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A. 1996. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 93:14665–14669.
  • Pike ACW, Rellos P, Niesen FH, Turnbull A, Oliver AW, Parker SA, Turk BE, Pearl LH, Knapp S. 2008. Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J. 27:704–714.
  • Pincus D, Letunic I, Bork P, Lim WA. 2008. Evolution of the phospho-tyrosine signaling machinery in premetazoan lineages. Proc Natl Acad Sci USA 105:9680–9684.
  • Pluk H, Dorey K, Superti-Furga G. 2002. Autoinhibition of c-Abl. Cell. 108:247–259.
  • Porter M, Schindler T, Kuriyan J, Miller WT. 2000. Reciprocal regulation of Hck activity by phosphorylation of Tyr(527) and Tyr(416). Effect of introducing a high affinity intramolecular SH2 ligand. J Biol Chem. 275:2721–2726.
  • Qiu H, Miller WT. 2002. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem. 277:34634–34641.
  • Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, Mohr RN, Bazan JF, Howard M, Copeland NG. 1993. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science. 261:358–361.
  • Register AC, Leonard SE, Maly DJ. 2014. SH2-catalytic domain linker heterogeneity influences allosteric coupling across the SFK family. Biochemistry. 53:6910–6923.
  • Resh MD. 1994. Myristylation and palmitylation of Src family members: the fats of the matter. Cell. 76:411–413.
  • Richter DJ, King N. 2013. The genomic and cellular foundations of animal origins. Annu Rev Genet. 47:509–537.
  • Sadowski I, Stone JC, Pawson T. 1986. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol. 6:4396–4408.
  • Saleh T, Rossi P, Kalodimos CG. 2017. Atomic view of the energy landscape in the allosteric regulation of Abl kinase. Nat Struct Mol Biol. 24:893–901.
  • Salim K, Bottomley MJ, Querfurth E, Zvelebil MJ, Gout I, Scaife R, Margolis RL, Gigg R, Smith CI, Driscoll PC, et al. 1996. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton’s tyrosine kinase. EMBO J. 15:6241–6250.
  • Sawyers CL. 2003. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17:2998–3010.
  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:1938–1942.
  • Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. 1999. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell. 3:639–648.
  • Schmitz R, Baumann G, Gram H. 1996. Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display. J Mol Biol. 260:664–677.
  • Schultheiss KP, Craddock BP, Suga H, Miller WT. 2014. Regulation of Src and Csk nonreceptor tyrosine kinases in the filasterean Ministeria vibrans. Biochemistry. 53:1320–1329.
  • Schultheiss KP, Suga H, Ruiz-Trillo I, Miller WT. 2012. Lack of Csk-mediated negative regulation in a unicellular SRC kinase. Biochemistry. 51:8267–8277.
  • Scott JD, Pawson T. 2000. Cell communication: the inside story. Sci Am. 282:72–79.
  • Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. 2007. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure. 15:299–311.
  • Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. 2009. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 69:2384–2392.
  • Segawa Y, Suga H, Iwabe N, Oneyama C, Akagi T, Miyata T, Okada M. 2006. Functional development of Src tyrosine kinases during evolution from a unicellular ancestor to multicellular animals. Proc Natl Acad Sci USA 103:12021–12026.
  • Shah NH, Löbel M, Weiss A, Kuriyan J. 2018. Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen. Elife. 7:e35190.
  • Shah NH, Wang Q, Yan Q, Karandur D, Kadlecek TA, Fallahee IR, Russ WP, Ranganathan R, Weiss A, Kuriyan J. 2016. An electrostatic selection mechanism controls sequential kinase signaling downstream of the T cell receptor. Elife.5:e20105.
  • Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117–125.
  • Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, Jensen MØ, Dror RO, Kuriyan J, Shaw DE. 2009. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA 106:139–144.
  • Shukla D, Meng Y, Roux B, Pande VS. 2014. Activation pathway of Src kinase reveals intermediate states as targets for drug design. Nat Commun. 5:3397
  • Sicheri F, Moarefi I, Kuriyan J. 1997. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:602–609.
  • Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, et al. 2006. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 103:19466–19471.
  • Smith CIE. 2017. From identification of the BTK kinase to effective management of leukemia. Oncogene. 36:2045–2053.
  • Sondhi D, Xu W, Songyang Z, Eck MJ, Cole PA. 1998. Peptide and protein phosphorylation by protein tyrosine kinase Csk: insights into specificity and mechanism. Biochemistry. 37:165–172.
  • Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C. 1995. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 373:536–539.
  • Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ. 1993. SH2 domains recognize specific phosphopeptide sequences. Cell. 72:767–778.
  • Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T. 1994. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol. 14:2777–2785.
  • Spector DH, Varmus HE, Bishop JM. 1978. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc Natl Acad Sci USA 75:4102–4106.
  • Srivastava M, Simakov O, Chapman J, Fahey B, Gauthier MEA, Mitros T, Richards GS, Conaco C, Dacre M, Hellsten U, et al. 2010. The Amphimedon queenslandica genome and the evolution of animal complexity. Nature. 466:720–726.
  • Stehelin D, Varmus HE, Bishop JM, Vogt PK. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 260:170–173.
  • Suga H, Dacre M, de Mendoza A, Shalchian-Tabrizi K, Manning G, Ruiz-Trillo I. 2012. Genomic survey of premetazoans shows deep conservation of cytoplasmic tyrosine kinases and multiple radiations of receptor tyrosine kinases. Sci Signal. 5:ra35.
  • Suga H, Miller WT. 2018. Src signaling in a low-complexity unicellular kinome. Sci Rep. 8:5362.
  • Suga H, Torruella G, Burger G, Brown MW, Ruiz-Trillo I. 2014. Earliest Holozoan expansion of phosphotyrosine signaling. Mol Biol Evol. 31:517–528.
  • Takesono A, Finkelstein LD, Schwartzberg PL. 2002. Beyond calcium: new signaling pathways for Tec family kinases. J Cell Sci. 115:3039–3048.
  • Taskinen B, Ferrada E, Fowler DM. 2017. Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase. J Biol Chem. 292:18518–18529.
  • Thomas JD, Sideras P, Smith CI, Vorechovský I, Chapman V, Paul WE. 1993. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 261:355–358.
  • Thomas JW, Ellis B, Boerner RJ, Knight WB, White GC, Schaller MD. 1998. SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem. 273:577–583.
  • Thomas SM, Brugge JS. 1997. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 13:513–609.
  • Till JH, Chan PM, Miller WT. 1999. Engineering the substrate specificity of the Abl tyrosine kinase. J Biol Chem. 274:4995–5003.
  • Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, et al. 1993. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 72:279–290.
  • Ubersax JA, Ferrell JE. 2007. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol. 8:530–541.
  • Väliaho J, Smith CIE, Vihinen M. 2006. BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 27:1209–1217.
  • Vetrie D, Vorechovský I, Sideras P, Holland J, Davies A, Flinter F, Hammarström L, Kinnon C, Levinsky R, Bobrow M. 1993. The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. Nature. 361:226–233.
  • von Rauszendorf F, de Ruiter A, Leonard TA. 2017. A switch in nucleotide affinity governs activation of the Src and Tec family kinases. Sci Rep.Rep. 7:17405.
  • Waksman G, Kominos D, Robertson SC, Pant N, Baltimore D, Birge RB, Cowburn D, Hanafusa H, Mayer BJ, Overduin M, et al. 1992. Crystal structure of the phosphotyrosine recognition domain SH2 of v-Src complexed with tyrosine-phosphorylated peptides. Nature. 358:646–653.
  • Waksman G, Kumaran S, Lubman O. 2004. SH2 domains: role, structure and implications for molecular medicine. Expert Rev Mol Med. 6:1–18.
  • Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J. 1993. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell. 72:779–790.
  • Wang JYJ. 2014. The capable ABL: what is its biological function? Mol Cell Biol. 34:1188–1197.
  • Wang Q, Vogan EM, Nocka LM, Rosen CE, Zorn JA, Harrison SC, Kuriyan J. 2015. Autoinhibition of Bruton’s tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate. Elife.4:e06074.
  • Wang Q, Zorn JA, Kuriyan J. 2014. A structural atlas of kinases inhibited by clinically approved drugs. Meth Enzymol. 548:23–67.
  • Weng Z, Rickles RJ, Feng S, Richard S, Shaw AS, Schreiber SL, Brugge JS. 1995. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol Cell Biol. 15:5627–5634.
  • Williams JC, Weijland A, Gonfloni S, Thompson A, Courtneidge SA, Superti-Furga G, Wierenga RK. 1997. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J Mol Biol. 274:757–775.
  • Wilson C, Agafonov RV, Hoemberger M, Kutter S, Zorba A, Halpin J, Buosi V, Otten R, Waterman D, Theobald DL, Kern D. 2015. Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug’s mechanism. Science. 347:882–886.
  • Witte ON, Dasgupta A, Baltimore D. 1980. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature. 283:826–831.
  • Wong L, Lieser SA, Miyashita O, Miller M, Tasken K, Onuchic JN, Adams JA, Woods VL, Jennings PA. 2005. Coupled motions in the SH2 and kinase domains of Csk control Src phosphorylation. J Mol Biol. 351:131–143.
  • Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH-H, Steggerda SM, Versele M, et al. 2014. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 370:2286–2294.
  • Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, Ji Q, Miller WT, Hubbard SR. 2008. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J. 27:1985–1994.
  • Wu W-I, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. 2010. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One.5:e12913.
  • Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, et al. 2017. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 543:733–737.
  • Xiong X, Cui P, Hossain S, Xu R, Warner B, Guo X, An X, Debnath AK, Cowburn D, Kotula L. 2008. Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1. Biochim Biophys Acta. 1783:737–747.
  • Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, Peterson JR, Dunbrack RL. 2015. Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Sci Signal. 8:rs13.
  • Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. 1999. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell. 3:629–638.
  • Xu W, Harrison SC, Eck MJ. 1997. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 385:595–602.
  • Yamaguchi H, Hendrickson WA. 1996. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 384:484–489.
  • Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. 2001. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 105:115–126.
  • Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. 1994. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell. 76:933–945.
  • Yu H, Rosen MK, Shin TB, Seidel-Dugan C, Brugge JS, Schreiber SL. 1992. Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science. 258:1665–1668.
  • Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. 2002. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 9:117–120.
  • Zheng J, Trafny EA, Knighton DR, Xuong NH, Taylor SS, Ten Eyck LF, Sowadski JM. 1993. 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr D Biol Crystallogr. 49:362–365.
  • Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. 1997. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett. 7:187–192.
  • Zorba A, Buosi V, Kutter S, Kern N, Pontiggia F, Cho Y-J, Kern D. 2014. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. Elife. 3:e02667.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.